Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,088.20 | 59.40 | 0.66% |
CAC 40 | 7,621.04 | 10.97 | -0.14% |
DAX 40 | 23,846.07 | 88.38 | 0.37% |
Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
FTSE 100 | 9,142.73 | 14.43 | 0.16% |
HKSE | 24,902.53 | 169.08 | 0.68% |
NASDAQ | 20,916.55 | 137.03 | -0.65% |
Nikkei 225 | 40,529.12 | 20.42 | -0.05% |
NZX 50 Index | 12,905.12 | 28.08 | 0.22% |
S&P 500 | 6,299.19 | 30.75 | -0.49% |
S&P/ASX 200 | 8,823.50 | 53.10 | 0.61% |
SSE Composite Index | 3,617.60 | 34.29 | 0.96% |